Skip to main content
. 2012 Feb 14;94(1):80–88. doi: 10.1016/j.antiviral.2012.02.004

Fig. 3.

Fig. 3

Accommodation of sequence mismatches by PMOplusTM therapeutics. Sequences represent an alignment of a generalized MARV consensus genome with the PMOplusTM molecules comprising AVI-6003. Positively charged piperazine groups (+) and inosine bases (I) are positioned in the molecules at sites where mismatches occur. Genomic sequences from representative MARV variants/isolates are shown as cDNA complementary to genomic RNA. The MARV isolates shown include those against which AVI-6003 has exhibited antiviral activity in in vivo models (mouse-adapted Ravn virus, guinea-pig adapted MARV-Musoke, and non-adapted MARV-Musoke), or which were isolated during outbreaks (Ang0998, 07DRC, 09DRC), or which may have been involved in weaponization programs (Poppinga).